Yahoo Finance

NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), a USD$37.99M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, ...
FierceBiotech

Imprimis Pharmaceuticals (immy) Names Seasoned Ophthalmology Executive John Saharek As Vice-President Of Commercialization For Its Ophthalmology Division

SAN DIEGO, Nov. 12, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a pharmaceutical company focused on commercializing novel drug formulations invented by physicians and ...
FierceBiotech

Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013

Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013 Imprimis Engages Agility ...
FiercePharma

Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Bleeding and Clotting Disorder Functional Antibiotic Drug Candidate

SAN DIEGO, July 23, 2013 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505(b)(2) drug development ...
Yahoo

Imprimis, a Turing rival, aims to undercut drug price hikes

NEW YORK (Reuters) - Imprimis Pharmaceuticals Inc (IMMY.O), the compounding pharmacy that makes a $1 copycat of Turing Pharmaceuticals' high priced Daraprim treatment, sees an opportunity to build a ...